

**California Bioscience** 

83103 Avenue 48, Ste.1B #204 Coachella, CA 92236 USA Phone : +1.6268339877 Email : info@cali-bio.com

# **Product Datasheet**

Product Name	Small Ubiquitin-Related Modifier 2 Human Recombinant
Cata No	CB501197
Source	Escherichia Coli.
Synonyms	SUMO-2, Ubiquitin-like protein SMT3B, SMT3 homolog 2, Sentrin-2 HSMT3, SUMO-3, Sentrin2, SUMO2, SMT3H2, MGC117191.

## Description

Small Ubiquitin-like Modifiers (SUMOs) are a family of small, related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed sumoylation. Unlike ubiguitination, which targets proteins for degradation, sumoylation participates in a number of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. All SUMO proteins share the conserved ubiquitin domain and the C-terminal diglycine cleavage/attachment site. Human SUMO2, also known as Sentrin2 and SMT3B is synthesized as a 95 amino acid (aa), 11 kDa propeptide that contains a two aa C-terminal prosegment, and an 18 aa N-terminal protein interacting region (aa 33 -50). Following prosegment cleavage, the C-terminal glycine is enzymatically attached to a lysine on a target protein. Human SUMO2 shares 100% sequence identity to SUMO-2 from mouse. SUMO2 also has very high sequence homology to SUMO3 and SUMO4, 86 % and 85%, respectively. SUMO2 shares only 44% sequence identity to SUMO1. SUMO2 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain

containing 95 amino acids and having a molecular mass of 11 kDa. The SUMO-2 is purified by proprietary chromatographic techniques.

### **Physical Appearance**

Sterile Filtered White lyophilized (freeze-dried) powder.

#### Purity

Greater than 95.0% as determined by:(a) Analysis by RP-HPLC.(b) Analysis by SDS-PAGE.

# Formulation

The SUMO2 was lyophiized from 1X PBS, pH 7.4.

#### Stability

Lyophilized SUMO2 although stable  $10^{\circ}$  for 1 week, should be stored desiccated below -18°C. Please prevent freeze-thaw cycles.

## Sequence

MADEKPKEGVKTENNDHINLKVAGQDGSVVQFKI KRHTPLSKLMKAYC ERQGLSMRQIRFRFDGQPINETDTPAQLEMEDED TIDVFQQQTGGVY